CD8 (delivery anchor) / IL-2 receptor

Class

Fusion protein (CD8+ T-cell-selective IL-2 immunocytokine, also known as etakafusp alfa)

Pathway

IL-2 receptor signaling selectively activated on CD8+ cytotoxic T-lymphocytes

Notes

original target text: CD8 (delivery anchor) / IL-2 receptor (effector, affinity-attenuated IL-2 mutein)

Interleukin-2 (IL-2) is a signaling protein that drives the growth and activity of T lymphocytes, immune cells that can recognize and destroy abnormal or infected cells. It works by binding to the IL-2 receptor, a receptor complex expressed at different levels on different immune cell types. Native IL-2 is difficult to use as a medicine because it activates not only CD8+ cytotoxic T cells, the subset most responsible for killing tumor cells, but also regulatory T cells that dampen immune responses, natural killer cells, and blood vessel lining cells, the last of which can cause fluid leakage from vessels. This mechanism addresses that problem by fusing a weakened ('affinity-attenuated') form of IL-2 to a targeting domain that binds CD8, using the CD8-binding portion as a delivery anchor to concentrate the cytokine on CD8+ T cells before the attenuated IL-2 portion engages its receptor. The intended result is preferential expansion and activation of cytotoxic T cells at the site where they are already present, while reducing activation of other IL-2-responsive cell populations. This approach belongs to a broader category of engineered, cell-selective cytokines being explored to improve the tumor-killing potential of immunotherapy while managing the systemic toxicity historically associated with cytokine therapy.